# Urology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Voltaire (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN002-SYN
- Date: 2026-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aurelio Bergström-Nwosu, MD
- Calendar frame: modern shifted

- Requested by: Honorine Delacroix-Mensah, MD

## Reason for consultation

An 83-year-old man with three weeks of visible blood in the urine with small clots, a weak stream, and chronic retention (post-void residual 460 mL) with acute kidney injury, now drained by an indwelling catheter. Please evaluate the hematuria with cystoscopy, advise on the retention and the voiding trial, and interpret his PSA. **S**

## History

Voltaire is seen at the request of Dr. Delacroix-Mensah, one week after a catheter was placed for chronic retention with gross hematuria. The urine in the bag has cleared from red to light pink, with one small clot four days ago. He has had no fever, flank pain, or catheter blockage. He describes several years of a slowing stream and getting up at night, worse over the past few months, and three weeks of visible blood. He has stopped the diphenhydramine and the phosphate enemas. He has never smoked, has no exposure to aromatic amines, has not had pelvic radiation or cyclophosphamide, has not travelled where schistosomiasis is common, and has no history of bladder stones. He takes no anticoagulant or antiplatelet drug. He is frank that he would not want major surgery if it meant months of recovery. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin, alert, and quick |
| Abdomen | Soft and non-tender; bladder not palpable with the catheter draining |
| Genitourinary | Normal external genitalia; catheter draining light pink urine; meatus clean |
| Rectal | Prostate enlarged, about 70 to 80 mL, firm and smooth, with no discrete nodule; no fixed pelvic mass felt |
| Cystoscopy | Flexible cystoscopy: trilobar prostatic enlargement with friable surface vessels; a solid, sessile, partly necrotic tumor about 4 cm on the posterior wall extending to the dome, with surrounding white keratinizing plaques; no other lesions; ureteric orifices clear. Catheter replaced |

BP 132/70 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 54 kg; BMI 18.7 kg/m². All vital signs are synthetic.

## Data reviewed

CT urography two days after intake: 4.2 cm sessile soft-tissue mass of the posterior bladder wall extending to the dome, wall thickened to 1.8 cm with perivesical stranding; no hydronephrosis; upper tracts clear; prostate about 78 mL with a median lobe; no enlarged nodes or bone lesions. Chest CT: clear. Urine culture: no growth. Urine cytology: atypical squamous cells suspicious for malignancy. Creatinine 1.68 mg/dL at intake and 1.24 mg/dL today (eGFR 58); hemoglobin 11.6 then 11.2 g/dL; PSA 6.4 ng/mL; IPSS 22 before the catheter; post-void residual 460 mL. Hemoglobin: 11.2 g/dL (low); Potassium: 4.6 mmol/L; BUN: 22 mg/dL; Creatinine: 1.24 mg/dL; eGFR: 58 mL/min/1.73 m² (low). All results are synthetic.

## Assessment

1. **Gross hematuria with difficult urination** (R31.0). The bleeding comes from a solid bladder tumor whose appearance and size, with wall thickening and perivesical stranding on CT, suggest a muscle-invasive cancer; the keratinizing plaques and squamous atypia on cytology raise the possibility of squamous histology. The friable prostatic vessels may add to the bleeding. The upper tracts are clear and the chest CT shows no metastasis. **S**
2. **Chronic urinary retention** (R33.8). Chronic high-pressure retention from prostatic obstruction, made worse by the anticholinergic sleep aid and possibly by clot and the tumor's bulk; kidney function has recovered with drainage. **S**
3. **Benign prostatic hyperplasia with lower urinary tract symptoms** (N40.1). PSA 6.4 ng/mL with a gland of about 78 mL gives a PSA density of 0.08, low, and the gland is smooth. Retention, catheterization, and bleeding all raise the PSA. At 83, with a bladder tumor that will determine his treatment and outlook, finding a prostate cancer now would not change management, so I do not advise prostate MRI or biopsy. **S**

## Recommendations

1. Transurethral resection of the bladder tumor with examination under anesthesia in two days, resecting into muscle for diagnosis and staging; one dose of perioperative antibiotic.
2. Keep the indwelling catheter until after the resection; then a trial without catheter on tamsulosin once he is free of infection, with a bladder scan after voiding; if he fails, intermittent self-catheterization or a long-term catheter rather than prostate surgery while the bladder cancer is treated.
3. Continue tamsulosin; no 5-alpha-reductase inhibitor for now.
4. No prostate MRI or biopsy, by shared decision; no further PSA testing unless it would change care.
5. If the resection confirms muscle-invasive cancer, complete staging is already in hand with the CT urography and chest CT; a geriatric assessment should precede the treatment decision, and the options to discuss are radical cystectomy, bladder-preserving radiotherapy, weekly palliative radiotherapy, and symptom care, weighed against his goals.
6. At home: catheter care, 1.5 to 2 liters of fluid a day, and urgent return or a call for a blocked catheter, large clots, fever, or rigors.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Delacroix-Mensah the same day. Voltaire agrees to the resection and asked that the pathology be explained to him plainly at his next primary care visit. **S**

## Follow-up

Resection in two days. I will review the pathology with Dr. Delacroix-Mensah and see him again if bleeding, clots, or retention return, or if he wishes to reconsider surgery. **S**

## Guideline basis

- Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025), American Urological Association and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024), American Urological Association
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026), National Comprehensive Cancer Network
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026), European Association of Urology
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023), American Urological Association
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018), American Society of Clinical Oncology
- Prostate Cancer: Screening (2018), U.S. Preventive Services Task Force
